Scott Megaffin

Mr. Megaffin has more than 30 years of related experience in the pharmaceutical industry. Scott plans and directs all aspects of Adastra operational objectives, policies and initiatives. He is responsible for corporate, commercial and clinical development-related functions at Adastra, including investor relations and communication of the corporate vision and supporting values.

Prior to joining Adastra, Mr. Megaffin was President of Churchill Pharmaceuticals LLC, sold to Sun Pharma in 2018. Scott has held numerous global strategic and operational positions of increasing responsibility including Senior Vice President of Commercial Development for Onconova Therapeutics, Inc., also Cephalon, Adolor, Yamounchi and Bristol-Myers Squibb. He has led six global drug approvals and development programs, within a variety of therapeutic categories including oncology, hematology, virology, critical care, anti-infectives, pain and inflammation. Scott received a B.S. in Biology from Pittsburg State University.